Change in the Clinical Picture of Hospitalized Patients with COVID-19 between the Early and Late Period of Dominance of the Omicron SARS-CoV-2 Variant

This study aimed to compare the clinical picture of COVID-19 in the initial and later period of Omicron dominance and to identify populations still at risk. A retrospective comparison of the clinical data of 965 patients hospitalized during the early period of Omicron’s dominance (EO, January–June 2022) with 897 patients from a later period (LO, July 2022–April 2023) from the SARSTer database was performed. Patients hospitalized during LO, compared to EO, were older, had a better clinical condition on admission, had a lower need for oxygen and mechanical ventilation, had less frequent lung involvement in imaging, and showed much faster clinical improvement. Moreover, the overall mortality during EO was 14%, higher than that in LO—9%. Despite the milder course of the disease, mortality exceeding 15% was similar in both groups among patients with lung involvement. The accumulation of risk factors such as an age of 60+, comorbidities, lung involvement, and oxygen saturation <90% resulted in a constant need for oxygen in 98% of patients, an 8% risk of mechanical ventilation, and a 30% mortality rate in the LO period. Multiple logistic regression revealed lower odds of death during the LO phase. Despite the milder course of infections caused by the currently dominant subvariants, COVID-19 prophylaxis is necessary in people over 60 years of age, especially those with comorbidities, and in the case of pneumonia and respiratory failure.

[1]  J. Haughney,et al.  Directions of change in intrinsic case severity across successive SARS-CoV-2 variant waves have been inconsistent , 2023, The Journal of infection.

[2]  E. Nicastri,et al.  Evolution of SARS‐CoV‐2 variants of concern over a period of Delta and Omicron cocirculation, among patients hospitalized for COVID‐19 in an Italian reference hospital: Impact on clinical outcomes , 2023, Journal of medical virology.

[3]  S. Madhi,et al.  SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines , 2023, Frontiers in Immunology.

[4]  A. Zoufaly,et al.  A retrospective analysis of clinical features of patients hospitalized with SARS-CoV-2 Omicron variants BA.1 and BA.2 , 2023, Scientific reports.

[5]  Xiawei Wei,et al.  The rapid rise of SARS‐CoV‐2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants , 2023, MedComm.

[6]  Wang-Qin Shen,et al.  Clinical outcomes of the severe acute respiratory syndrome coronavirus 2 Omicron and Delta variant: systematic review and meta-analysis of 33 studies covering 6 037 144 coronavirus disease 2019–positive patients , 2023, Clinical Microbiology and Infection.

[7]  Lu Lu,et al.  SARS‐CoV‐2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan‐coronavirus fusion inhibitors , 2023, Journal of medical virology.

[8]  D. De Cock,et al.  Surfing the Waves: Differences in Hospitalised COVID-19 Patients across 4 Variant Waves in a Belgian University Hospital , 2023, Viruses.

[9]  Lu Lu,et al.  SARS-CoV-2 Omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors , 2023, Emerging microbes & infections.

[10]  Xinbing Sui,et al.  Omicron subvariant BA.5 is highly contagious but containable: Successful experience from Macau , 2023, Frontiers in Public Health.

[11]  S. Joshi,et al.  Clinical Characteristics and Outcomes of Laboratory-Confirmed SARS-CoV-2 Cases Infected With Omicron Subvariants and the XBB Recombinant Variant , 2023, medRxiv.

[12]  R. Flisiak,et al.  Variability in the Clinical Course of COVID-19 in a Retrospective Analysis of a Large Real-World Database , 2023, Viruses.

[13]  M. Bhattacharya,et al.  A Detailed Overview of SARS-CoV-2 Omicron: Its Sub-Variants, Mutations and Pathophysiology, Clinical Characteristics, Immunological Landscape, Immune Escape, and Therapies , 2023, Viruses.

[14]  H. Sbihi,et al.  Clinical severity of Omicron subvariants BA.1, BA.2, and BA.5 in a population‐based cohort study in British Columbia, Canada , 2022, Journal of medical virology.

[15]  L. Danon,et al.  Severity of Omicron (B.1.1.529) and Delta (B.1.617.2) SARS-CoV-2 infection among hospitalised adults: A prospective cohort study in Bristol, United Kingdom , 2022, The Lancet Regional Health - Europe.

[16]  M. Kiso,et al.  Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB , 2022, The New England journal of medicine.

[17]  E. Klein,et al.  Omicron Subvariants: Clinical, Laboratory, and Cell Culture Characterization , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  A. Nardone,et al.  Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies , 2022, PLoS medicine.

[19]  H. Ullum,et al.  Risk of reinfection, vaccine protection, and severity of infection with the BA.5 omicron subvariant: a nation-wide population-based study in Denmark , 2022, The Lancet Infectious Diseases.

[20]  Y. Teng,et al.  The outbreak of SARS‐CoV‐2 Omicron lineages, immune escape, and vaccine effectivity , 2022, Journal of medical virology.

[21]  J. Zahradník,et al.  Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5 , 2022, Cell.

[22]  H. van Bakel,et al.  Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants , 2022, The New England journal of medicine.

[23]  R. Flisiak,et al.  Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance , 2022, Pharmacological Reports.

[24]  M. Mendelson,et al.  Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province, South Africa , 2022, International Journal of Infectious Diseases.

[25]  A. von Gottberg,et al.  Clinical severity of omicron lineage BA.2 infection compared with BA.1 infection in South Africa , 2022, The Lancet.

[26]  Jong Hyuk Lee,et al.  Chest CT Findings in Hospitalized Patients with SARS-CoV-2: Delta versus Omicron Variants , 2022, Radiology.

[27]  F. Gleeson,et al.  Reduction in Chest CT Severity and Improved Hospital Outcomes in SARS-CoV-2 Omicron Compared with Delta Variant Infection , 2022, Radiology.

[28]  Gheyath K Nasrallah,et al.  Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections , 2022, The New England journal of medicine.

[29]  Fei Shao,et al.  BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection , 2022, Nature.

[30]  M. Lipsitch,et al.  Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California , 2022, Nature Medicine.

[31]  M. S. Islam,et al.  Is the SARS CoV-2 Omicron Variant Deadlier and More Transmissible Than Delta Variant? , 2022, International journal of environmental research and public health.

[32]  K. Simon,et al.  Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of February 23, 2022. , 2022, Polish archives of internal medicine.

[33]  H. Jacquier,et al.  Comparison of Patients Infected With Delta Versus Omicron COVID-19 Variants Presenting to Paris Emergency Departments , 2022, Annals of Internal Medicine.

[34]  J. Dushoff,et al.  Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa , 2022, Science.

[35]  M. Exline,et al.  Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study , 2022, BMJ.

[36]  Gheyath K Nasrallah,et al.  Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage , 2022, Nature Communications.

[37]  I. Abeyagunawardena,et al.  A comparison of transmissibility of SARS-CoV-2 variants of concern , 2022, Virology Journal.

[38]  P. Noble,et al.  Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance — One Hospital, California, July 15–September 23, 2021, and December 21, 2021–January 27, 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[39]  Q. Ye,et al.  The emergence and epidemic characteristics of the highly mutated SARS‐CoV‐2 Omicron variant , 2022, Journal of medical virology.

[40]  K. Simon,et al.  Management of SARS-CoV- infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of April 26, 2021. , 2021, Polish archives of internal medicine.

[41]  P. Cinque,et al.  Smell and taste disorders in COVID-19: From pathogenesis to clinical features and outcomes , 2021, Neuroscience Letters.

[42]  N. Schröter,et al.  Anosmia in COVID-19 patients , 2020, Clinical Microbiology and Infection.

[43]  Lei Dong,et al.  Kidney disease is associated with in-hospital death of patients with COVID-19 , 2020, Kidney International.